Cargando…
Multi-Target Approaches in Metabolic Syndrome
Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994619/ https://www.ncbi.nlm.nih.gov/pubmed/33776749 http://dx.doi.org/10.3389/fphar.2020.554961 |
_version_ | 1783669790542397440 |
---|---|
author | Lillich, Felix F. Imig, John D. Proschak, Ewgenij |
author_facet | Lillich, Felix F. Imig, John D. Proschak, Ewgenij |
author_sort | Lillich, Felix F. |
collection | PubMed |
description | Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to drug-drug interactions and inadequate patient adherence, resulting in poor management of the disease. Multi-target approaches aim at reducing the polypharmacology and improving the efficacy. This review summarizes the medicinal chemistry efforts to develop multi-target ligands for MetS. Different combinations of pharmacological targets in context of in vivo efficacy and future perspective for multi-target drugs in MetS are discussed. |
format | Online Article Text |
id | pubmed-7994619 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79946192021-03-27 Multi-Target Approaches in Metabolic Syndrome Lillich, Felix F. Imig, John D. Proschak, Ewgenij Front Pharmacol Pharmacology Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to drug-drug interactions and inadequate patient adherence, resulting in poor management of the disease. Multi-target approaches aim at reducing the polypharmacology and improving the efficacy. This review summarizes the medicinal chemistry efforts to develop multi-target ligands for MetS. Different combinations of pharmacological targets in context of in vivo efficacy and future perspective for multi-target drugs in MetS are discussed. Frontiers Media S.A. 2021-03-12 /pmc/articles/PMC7994619/ /pubmed/33776749 http://dx.doi.org/10.3389/fphar.2020.554961 Text en Copyright © 2021 Lillich, Imig and Proschak. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lillich, Felix F. Imig, John D. Proschak, Ewgenij Multi-Target Approaches in Metabolic Syndrome |
title | Multi-Target Approaches in Metabolic Syndrome |
title_full | Multi-Target Approaches in Metabolic Syndrome |
title_fullStr | Multi-Target Approaches in Metabolic Syndrome |
title_full_unstemmed | Multi-Target Approaches in Metabolic Syndrome |
title_short | Multi-Target Approaches in Metabolic Syndrome |
title_sort | multi-target approaches in metabolic syndrome |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994619/ https://www.ncbi.nlm.nih.gov/pubmed/33776749 http://dx.doi.org/10.3389/fphar.2020.554961 |
work_keys_str_mv | AT lillichfelixf multitargetapproachesinmetabolicsyndrome AT imigjohnd multitargetapproachesinmetabolicsyndrome AT proschakewgenij multitargetapproachesinmetabolicsyndrome |